Minvasys to focus on innovative systems:
This article was originally published in Clinica
Executive Summary
A focus on developing innovative systems will be among the business aims of Minvasys, a new name in the French interventional vascular device sector. The company was formed in May, following the acquisition by Pierre Hilaire of all the share capital of Cathnet-Science France. Mr Hilaire is the president and managing director of Minvasys, which has 28 staff and headquarters in central Paris. The company will seek to combine its industry expertise and experience in serving the interventional medical community in Europe and worldwide, via its international business partners. Europe, Asia and Latin America are the company's main markets. Minvasys will continue to manufacture and market the haemostatic valve, SuperKetch, PTCA balloons, stent devices and a neuroradiology line.